Interventional × Triple Negative Breast Neoplasms × Genitourinary × Clear all
NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled
NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

Phase 1/2 Recruiting
300 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

City of Hope Medical Center

Phase 1 Active not recruiting
11 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT06781983 2026-01-07

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Innate Pharma

Phase 1 Recruiting
145 enrolled
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

Phase 1/2 Active not recruiting
81 enrolled
NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
NCT05958199 2025-06-27

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

NextPoint Therapeutics, Inc.

Phase 1 Suspended
131 enrolled